Control in congenital adrenal hyperplasia monitored by frequent saliva 17OH-progesterone measurements.
Treatment in a group of 19 patients with congenital adrenal hyperplasia (CAH) has been monitored by frequent, serial measurements of saliva 17OH-progesterone (17OHP) concentrations. Detailed 17OHP profiles were obtained during consecutive weekend days and every 1-2 h over a separate 24-hour period. Patients showed a marked diurnal rhythm in 17OHP levels, particularly when treated with hydrocortisone. In some patients, 10 mg/m2/day of hydrocortisone was sufficient glucocorticoid replacement to produce adequate control, although there was considerable individual variation. Saliva 17OHP profiles provided valuable information on the efficacy of hydrocortisone, cortisone acetate, prednisolone and dexamethasone as glucocorticoid suppressive regimes in the treatment of CAH. Preliminary results suggest that hydrocortisone given in two divided doses during the day, supplemented by a small dose of prednisolone at bedtime, is suitable treatment for CAH patients who are still growing. In the patient who has completed statural growth, single daily dose dexamethasone therapy ensures adequate adrenal suppression and is convenient in the longterm.
D019326:17-alpha-Hydroxyprogesterone; D000293:Adolescent; D000312:Adrenal Hyperplasia, Congenital / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D002940:Circadian Rhythm / Q000187:drug effects; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D006908:Hydroxyprogesterones / Q000032:analysis*; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage; D011863:Radioimmunoassay; D012463:Saliva / Q000032:analysis*
D005938:Glucocorticoids; D006908:Hydroxyprogesterones; D019326:17-alpha-Hydroxyprogesterone; D003907:Dexamethasone; D011239:Prednisolone; D006854:Hydrocortisone